# Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)

> **NCT00928512** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 237 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Secukinmab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00928512
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 237 (ACTUAL)
- **Last updated:** 2015-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00928512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00928512, "Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT00928512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*